Safety Profile
BPC-157 Side Effects: Frequency & Severity
BPC-157 has a favorable safety profile in animal studies with no serious adverse events reported in rodent toxicology. Human safety data is limited.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Common side effects
1Injection site reactions
Mild soreness, redness, or warmth at injection sites.
Uncommon side effects
3Headache
Reported anecdotally; mechanism unclear.
Dizziness
Typically mild and transient.
GI upset
Mild nausea or altered bowel patterns reported.
Rare side effects
3Fatigue
Reported in some user anecdotes.
Hypotension
Transient blood pressure reduction reported.
Allergic reactions
Hypersensitivity to the peptide or excipients.
Contraindications
- Known hypersensitivity
- Active malignancy (due to angiogenic activity — theoretical concern)
- Pregnancy and breastfeeding (insufficient safety data)
Drug interactions
- Limited published interaction data
- Theoretical interaction with other angiogenic factors
- Use with NSAIDs may be complementary (preclinical data suggests BPC-157 protects against NSAID GI damage)
Special populations
No human data in pregnancy, pediatrics, or elderly. Not approved in any jurisdiction.
Overall safety summary
BPC-157 has a clean preclinical safety record with no serious toxicity observed in rodent studies. Human safety data is limited to case reports and user surveys. The theoretical concern about angiogenic stimulation in malignancy remains unresolved.
BPC-157 side effects: FAQ
Is BPC-157 safe for long-term use?
Long-term human safety data does not exist. Animal studies show no serious adverse effects, but rodent lifespan is limited. Use should be short-term and under medical supervision.
Can BPC-157 cause cancer?
There is no evidence BPC-157 causes cancer. However, its pro-angiogenic mechanism is a theoretical concern in patients with existing malignancy, since tumors depend on angiogenesis.